Steven Kelly, President and CEO of Carisma Therapeutics, Named Ernst & Young Entrepreneur of the Year 2022 Greater Philadelphia

June 27, 2022

Steven Kelly, President and CEO of Carisma Therapeutics, Named Ernst & Young Entrepreneur of the Year 2022 Greater Philadelphia Award recognizes the most ambitious leaders who are building and sustaining successful, dynamic businesses around the world. PHILADELPHIA, June 27, 2022 – Carisma Therapeutics, a clinical stage biopharmaceutical company focused on...

Carisma Therapeutics to Host Webcast on Phase 1 Clinical Trial of Engineered Macrophage Therapy

June 17, 2022

Carisma Therapeutics, a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, will be hosting a webcast on June 24th at 1:00pm ET to present and discuss the latest data from its landmark, first-in-human chimeric antigen receptor macrophages (CAR-M) study of leading asset CT-0508 for the treatment of HER2 overexpressing solid tumors.

Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology

January 10, 2022

Collaboration will combine Carisma’s engineered macrophage technology with Moderna’s mRNA and LNP technologies to generate and develop in vivo CAR-M therapeutics Multi-year research collaboration funded by Moderna with options for up to twelve targets Carisma to receive $45 million up-front cash payment and investment by Moderna in the form of a $35...